abstract |
The invention relates to a pharmaceutical combination to be administered topically or orally of a non-sedative anti-histamine, with the exception of compounds of the loratadine type, and a leukotriene antagonist, selected from a leukotriene D4 antagonist, or a 5-lipoxygenase inhibitor, or a FLAP antagonist and optionally conventional, physiologically harmless supports, extenders and auxiliary agents, for the prophylaxis and treatment of allergic and/or vasomotor rhinitis or allergic conjunctivitis. |